PolyU students win gold medal in iGEM Competition 2024 with novel dual-targeting nanobody to overcome drug resistance in pancreatic cancer cells
A team of students from The Hong Kong Polytechnic University (PolyU) has won a gold medal and been listed among the top 10 undergraduate teams at the International Genetically Engineered Machine (iGEM) 2024 Grand Jamboree held in Paris. They also received dual nominations for Best Oncology Project and Best New Composite Part. Centred on the development of a novel dual-targeting nanobody to address gemcitabine resistance in pancreatic cancer patients, the winning project demonstrated exceptional potential for advancing innovation in cancer treatment and research, as well as broader application in synthetic biology.
Pancreatic cancer has a higher mortality rate than many other major cancers and is the fourth leading cause of cancer-related deaths in Hong Kong. Traditional treatments face challenges such as lack of targeted therapies and the low efficiency of chemotherapy and radiotherapy due to drug resistance, particularly to gemcitabine, a standard chemo-therapeutic agent. This is indicative of a concerning trend of decreasing sensitivity to first-line treatments for early-stage pancreatic cancer.
The PolyU team has developed a novel strategy to overcome this treatment challenge. Through bioinformatic analysis, they identified two crucial cell surface receptors, namely EGFR and HER2, which significantly correlate with tumour growth and resistance to gemcitabine in pancreatic cancer. Based on these findings, the team designed “Panobody”, a dual-targeting nanobody that can specifically block EGFR and HER2 and their signalling pathways. Subsequent experiments on Panobody, both used alone and in combination with gemcitabine, verified its effectiveness in inhibiting pancreatic cancer cell growth and even increasing their responsiveness to gemcitabine therapy.
Competing with 195 undergraduate teams from around the world, the interdisciplinary team of 11 students from the Department of Applied Biology and Chemical Technology and the Department of Electrical and Electronic Engineering spent eight months in rigorous laboratory work and comprehensive project development, while also consulting prominent clinical experts with extensive experience in pancreatic cancer treatment. Additionally, they conducted various innovative public engagement initiatives to promote awareness about pancreatic cancer, including creating an interactive educational game, setting up community booths and collaborating with the Hong Kong Cancer Fund for charity donation.
The team was under the guidance of Prof. Terence LEE, Associate Head and Professor of the Department of Applied Biology and Chemical Technology and other experts at PolyU. Prof. Lee applauded the team’s dedication to both scientific excellence and public engagement, and remarked, “This outstanding result not only recognises the high quality, impact and ingenuity of their work, but also highlights PolyU’s commitment to nurturing the next generation of biotechnology leaders.”
The iGEM Competition, established by the Massachusetts Institute of Technology (MIT) in 2004, is an annual, worldwide synthetic biology event aimed at undergraduate university students, as well as high school and graduate students. The Competition challenges participants to address real-world problems by designing, building, testing and measuring a system of their own design using interchangeable biological parts and standard molecular biology techniques.
For more details about the winning project, please visit: https://2024.igem.wiki/hkpolyu/
香港理工大學(理大)學生團隊早前於在巴黎舉行的2024年國際遺傳工程機器設計競賽(iGEM)勇奪金獎,更被評選為本科生組別的十強隊伍,同時獲得「Best Oncology Project」及「Best New Composite Part」兩項大獎的提名。得獎項目聚焦研發一種新型雙靶向納米抗體,助應對胰臟癌病人對治療藥物產生抗藥性的問題,具潛力推動創新的癌症治療和相關研究,並廣泛應用於合成生物學領域。
胰臟癌死亡率高於許多常見癌症,更是香港致命癌症的第四位。然而,傳統治療方案面對不少挑戰,例如標靶藥物不足以及病人對藥物產生抗藥性導致治療效果不佳。這些問題尤其常見於標準化療藥物「吉西他濱(gemcitabine)」上,令早期胰臟癌病人對第一線治療的敏感度往往會逐漸下降。
理大學生團隊嘗試研發創新的解決方案,應對這些治療困難。他們利用生物資訊分析,找出兩種與胰臟癌腫瘤生長和產生抗藥性的情況有重要關聯的細胞表面受體EGFR和HER2,然後設計出一種雙靶向納米抗體「Panobody」,能同時阻斷EGFR和HER2及其訊號傳遞路徑。團隊並通過隨後的實驗發現,無論是單獨使用「Panobody」或同時取用「Panobody」和「吉西他濱」,均有效抑制胰臟癌細胞生長,甚至提高癌細胞對「吉西他濱」治療的反應。
這支跨學科學生團隊由11名分別來自應用生物及化學科技學系及電機及電子工程學系的學生組成,在來自全球的195支本科生隊伍中突圍而出。參賽的八個月間,團隊除了在實驗室進行嚴謹的研究工作,亦諮詢了擁有豐富臨床胰臟癌治療經驗的專家。此外,他們更設計一系列公眾參與活動,包括製作互動教育遊戲、於社區設置攤位等,並支持了香港癌症基金會的籌款活動,冀提高社會對胰臟癌的關注。
學生團隊獲理大應用生物及化學科技學系副系主任及教授李建華教授及其他專家提供指導。李建華教授讚揚學生在參賽過程中努力追求科學卓越及提高公眾關注,並表示:「這次的優秀成績不但肯定了他們高質素、具影響力和創新的研究工作,亦突顯了理大致力培養新一代生物科技人才。」
國際遺傳工程機器設計競賽由麻省理工大學於2004年創辦,是全球合成生物學界的年度盛事,吸引來自世界各地的高中生、大專生及研究生參與。競賽旨在鼓勵參加者利用可交替的生物元件及分子生物技術設計並建立一套系統,解決社會實際面對的難題。
有關理大學生團隊的得獎項目,可瀏覽:https://2024.igem.wiki/hkpolyu/。